• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cells . IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients

tetano

Editor, Senior Moderator
Cells


. 2020 Dec 12;9(12):E2676.
doi: 10.3390/cells9122676.
IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients


L?onie A N Staats[SUP] 1 2 [/SUP], Hella Pfeiffer[SUP] 3 [/SUP], Jasmin Knopf[SUP] 2 4 [/SUP], Aylin Lindemann[SUP] 1 2 [/SUP], Julia F?rst[SUP] 1 2 [/SUP], Andreas E Kremer[SUP] 1 2 [/SUP], Holger Hackstein[SUP] 3 [/SUP], Markus F Neurath[SUP] 1 2 [/SUP], Luis E Mu?oz[SUP] 2 4 [/SUP], Susanne Achenbach[SUP] 3 [/SUP], Moritz Leppkes[SUP] 1 2 [/SUP], Martin Herrmann[SUP] 2 4 [/SUP], Georg Schett[SUP] 2 4 [/SUP], Ulrike Steffen[SUP] 2 4 [/SUP]



Affiliations

Abstract

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to an adaptive immune response in the host and the formation of anti-SARS-CoV-2 specific antibodies. While IgG responses against SARS-CoV-2 have been characterized quite well, less is known about IgA. IgA2 activates immune cells and induces inflammation and neutrophil extracellular trap (NET) formation which may contribute to organ injury and fatal outcome in SARS-CoV-2-infected patients. SARS-CoV-2 spike protein specific antibody levels were measured in plasma samples of 15 noninfected controls and 82 SARS-CoV-2-infected patients with no or mild symptoms, moderate symptoms (hospitalization) or severe disease (intensive care unit, ICU). Antibody levels were compared to levels of C-reactive protein (CRP) and circulating extracellular DNA (ecDNA) as markers for general inflammation and NET formation, respectively. While levels of SARS-CoV-2-specific IgG were similar in all patient groups, IgA2 antibodies were restricted to severe disease and showed the strongest discrimination between nonfatal and fatal outcome in patients with severe SARS-CoV-2 infection. While anti-SARS-CoV-2 IgG and IgA2 levels correlated with CRP levels in severely diseased patients, only anti-SARS-CoV-2 IgA2 correlated with ecDNA. These data suggest that the formation of anti-SARS-CoV-2 IgA2 during SARS-CoV-2 infection is a marker for more severe disease related to NET formation and poor outcome.

Keywords: COVID-19; IgA; SARS-CoV-2; inflammation; neutrophil extracellular trap (NET).
 
Back
Top Bottom